Research and Development
31 January 2018
We are looking for an experienced academic for a new position in Analytical Research & Development, that will provide scientific and project management leadership and coordination for analytical development activities.
The department is part of Chemical and Pharmaceutical Research (CPR). CPR is responsible for the CMC development and innovation of new drug candidates within depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. We strive to develop new innovating treatments to help improve the lives of the patients suffering from these diseases.
In Analytical Research and Development we are 26 highly skilled colleagues supporting the R&D organisation with expertise in analytical tasks. The department works with both small molecules and biologics from late discovery to product launch, and are responsible for analytical tasks irrespectively of done internally or at CMO partners
Your job and key responsibilities
You will be responsible for the analytical development in our global development projects within our highly integrated CMC project organization. You will lead the analytical development for API’s and IMP for clinical studies, and ensuring sufficient quality of release- and stability analyses, and coordination of project activities across the organization.
You will be an active member of the CMC focus team(s), and your responsibilities include:
Our preferred candidate has the following personal and professional qualifications:
For further information, please contact Director Analytical Research and Development, Christine Weber on CHW@lundbeck.com. Your application and CV should not be sent via email. We also recommend that you have a look at our website.
Please click on the link below to apply for the job. Applications must be received no later than 31 Jan 2018.
Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.
Read more at http://www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck .
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders.
Become part of Lundbeck's professional network to stay up-to-date with our worldwide career opportunities.Go to LinkedIn
Stay updated with the latest news and conversations around Lundbeck and our business.Go to Twitter
Learn about our disease areas and hear stories by patients living with psychiatric and neurological disorders.Go to YouTube